Neurocrine Biosciences reports Q1 2026 sales $811M (up 44%); agrees to acquire Soleno Therapeutics for $2.9B

NEUROCRINE BIOSCIENCES INC

2026-Q1 EPS reported $1.91 revenue$814,500,000

Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).
Definitive agreement to acquire Soleno Therapeutics for $53.00 per share ($2.9B equity value), expected to close in Q2 2026.
Initiated Phase 2 study of NBI-1117570 (dual M1/M4 agonist) for schizophrenia and Phase 1 study of NBIP-’2118 (CRF2 agonist) for obesity.
Reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7-$2.8 billion and total cash of $2.65 billion at March 31, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

NEUROCRINE BIOSCIENCES INC reported first quarter ended March 31, 2026 results: revenue 814.5 million dollars, net income 197.9 million dollars, EPS 1.91 dollars per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: 814.5 million dollars
Net income: 197.9 million dollars
EPS: 1.91 dollars per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO , May 5, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.